Skip to main content

Table 3 Pre–post differences in number of WIE, Wexner score and VAS by cause of FI (ITT)

From: Skeletal muscle-derived cell implantation for the treatment of sphincter-related faecal incontinence

 

Muscle damage

(N = 16)

Atrophy (N = 17)

Both

(N = 6)

WIE

 V2 – V0

−6.83 (7.13) (− 10.6; – 3.0)*

−6.17 (5.30) (− 8.9; – 3.4)*

−10.58 (8.54) (− 19.5; – 1.6)*

 V3 – V0

−9.25 (9.67) (− 14.4; – 4.1)*

−8.55 (7.12) (− 12.2; – 4.9)*

−19.79 (15.23) (− 35.8; – 3.8)*

 V4 – V0

− 9.29 (10.08) (−14.7; – 3.9)*

−8.09 (5.83) (− 11.1; – 5.1)*

−23.33 (13.14) (− 19.5; – 1.6)*

Wexner score

 V2 – V0

−13.44 (5.23) (− 16.2; – 10.7)*

−16.82 (3.81) (− 18.8; – 14.9)*

− 15.33 (3.50) (− 19.0; – 11.7)*

 V3 – V0

−14.25 (4.99) (− 16.2; – 10.7)*

−18.29 (2.39) (− 19.5; – 17.1)*

−14.50 (4.97) (− 19.7; – 9.3)*

 V4 – V0

− 14.94 (4.42) (− 16.9; – 11.6)*

−17.71 (1.99) (− 18.7; – 16.7)*

−17.67 (3.14) (− 21.0; – 14.4)*

VAS

 V2 – V0

−2.79 (2.11) (− 3.9; – 1.7)*

−3.07 (2.40) (− 4.4; – 1.7)*

−2.37 (1.72) (− 4.2; – 0.6)*

 V3 – V0

−3.65 (− 2.60) (− 5.0; – 2.3)*

−4.23 (2.41) (− 5.6; – 2.8)*

−4.10 (1.47) (− 5.9; – 2.3)*

 V4 – V0

−3.71 (2.84) (− 5.2; – 2.2)*

− 4.45 (2.35) (− 5.8; – 3.1)*

−5.89 (2.45) (− 9.8; – 2.0)*

  1. Data presented as mean (standard deviation) (95% confidence interval)
  2. WIE weekly incontinence episodes, VAS visual analogue scale, FI faecal incontinence, ITT intention-to-treat, N number of values, V visit, V0 implantation, V2, V3 and V4 1, 6 and 12 months post implantation
  3. *Significant change from baseline according to 95% confidence interval